Trials / Completed
CompletedNCT02716766
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
Randomised Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) Versus Single Agent Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- The University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if sorafenib, capecitabine and oxaliplatin (SECOX) regimen is more effective than sorafenib alone in the treatment of advanced liver cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | PO |
| DRUG | Capecitabine | PO |
| DRUG | Oxaliplatin | IV |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2018-09-01
- Completion
- 2018-09-01
- First posted
- 2016-03-23
- Last updated
- 2020-04-10
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT02716766. Inclusion in this directory is not an endorsement.